Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
R483 is a thiazolidinedione peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist with anti-diabetic properties and also a cytochrome P450 2C19 (CYP2C19) substrate. The aim of the clinical studies reported here was to investigate the influence of the CYP2C19 genotype on the pharmacok...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Published: |
Springer Verlag (Germany)
2010
|
| Subjects: |